Novo Nordisk, the Danish company that makes diabetes drug Ozempic and obesity treatment Wegovy, has begun work on a 5.3ha quality control centre in Hillerød, about 20km north of Copenhagen.
The facility will cost €390m to build, the largest investment the company has made in advanced quality control.
The company needs the centre to manage its new products and fast-expanding manufacturing capacity, said Erik Lorin Rasmussen, head of product supply.
In the past year, it has begun work on two large production sites in the US and Germany (see further reading).
Rasmussen said the plant would help the company “meet the changing demands of patients and regulators”.
The centre will consolidate a number of sites in Denmark to support future expansions.
Construction is expected to finish in 2027.
- Subscribe here to get stories about construction around the world in your inbox three times a week
Further reading:
Story for GCR? Get in touch via email: [email protected]
